

FORM PTO-1390 (REV 10-94)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 7885.65USWO
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. <b>09/331376</b> (If known, use 37 CFR 1.52)
INTERNATIONAL APPLICATION NO. PCT/NO97/00342	INTERNATIONAL FILING DATE December 16, 1997	PRIORITY DATE CLAIMED December 20, 1996	
TITLE OF INVENTION METHOD FOR CHARACTERIZATION OF ABNORMAL CELLS			
APPLICANT(S) FOR DO/EO/US Oystein FODSTAD; Hanne Kleppe HOIFODT			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol> <p><b>Items 11. to 16. below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.  <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information: Copy of Preliminary Examination Report; Verified Statement Claiming Small Entity Status</li> </ol>			

U.S. APPLICATION NO (If known, see 37 C.F.R. 1.5)		INTERNATIONAL APPLICATION NO PCT/NO97/00342		ATTORNEY'S DOCKET NUMBER 7885.65USWO	
---	--	--	--	---	--

17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):</b> Search Report has been prepared by the EPO or JPO.....\$840.00  International preliminary examination fee paid to U.S. Patent and Trademark Office (37 CFR 1.492(a)(1)).....\$670.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(3)) paid to USPTO .....\$970.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$96.00				<b>CALCULATIONS      PTO USE ONLY</b>	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$970.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14                      -20 = 0		X \$18.00	\$0	
Independent claims	1                              -3 = 0		X \$78.00	\$0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$970.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$485.00	
<b>SUBTOTAL =</b>				\$485.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$	
<b>TOTAL NATIONAL FEE =</b>				\$485.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$	
<b>TOTAL FEES ENCLOSED =</b>				\$485.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ Check(s) in the amount of \$485.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
 overpayment to Deposit Account No. 13-2725.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO  
 Michael B. Lasky  
 MERCHANT & GOULD  
 3100 Norwest Center  
 90 South Seventh Street  
 Minneapolis, MN 55403

  
 \_\_\_\_\_  
 SIGNATURE  
  
 \_\_\_\_\_  
 NAME  
  
 \_\_\_\_\_  
 29,555  
 REGISTRATION NUMBER

## INDEPENDENT INVENTOR(S)

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) and 1.27(b)) - INDEPENDENT INVENTORInsert title of  
application

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled Method for characterization of abnormal cells described in

Check one,  
fill in if b)  
or c)

- a) ☐ the specification filed herewith.  
b) ☐ application serial no. \_\_\_\_\_ filed \_\_\_\_\_  
c) ☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

Check one

- a) ☒ no such person, concern, or organization  
b) ☐ persons, concerns or organizations listed below

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

If to insert  
co-owners

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
a) ☐ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
a) ☐ INDIVIDUAL b) ☐ SMALL BUSINESS CONCERN c) ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereof, or any patent to which this verified statement is directed.

Insert each  
inventor

Hanne Kleppe Høifødt Øystein Fodstad  
NAME OF INVENTOR NAME OF INVENTOR NAME OF INVENTOR

Sign

Hanne Kleppe Høifødt Øystein Fodstad  
Signature of Inventor Signature of Inventor Signature of Inventor

Date

27/5-99 27/5-99  
Date Date Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FODSTAD, et al Docket No.: 7885.65USWO  
Serial No.: Unknown Filed: Concurrently Herewith  
Int'l Appln No.: PCT/NO97/00342 Int'l Filing Date: December 16, 1997  
Title: METHOD FOR CHARACTERIZATION OF ABNORMAL CELLS

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EL353244422US

Date of Deposit: June 18, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Tyrone Ross

PRELIMINARY AMENDMENT

Box PCT  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment based on claims amended in prosecution of the international application and published in the International Preliminary Examination Report, a copy of which is enclosed herewith:

IN THE ABSTRACT

Insert the attached Abstract page into the application as the last page thereof.

IN THE SPECIFICATION

A courtesy copy of the originally-filed PCT specification is enclosed herewith, but the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

## IN THE CLAIMS

In claim 3, line 1, delete "and 2".

In claim 5, line 1, delete "-4".

In claim 7, line 1, delete "claims 5-6" and insert --claim 5--.

In claim 9, line 1, delete "-8".

In claim 14, line 1, delete "according to claim 1-8" and insert -- to detect and phenotype target cells, such as animal and human cells, in cell suspensions by using particles coated with antibodies/ligands directed against antigenic determinants/receptors expressed on the target cells, except when the target cells are malignant and normal haematopoietic and lymphatic cells, characterized in that 2 - 6 antibodies or ligands, each antibody or ligand conjugated to each of several types of particles instrumentally or visually separable by fluorescence, color and size, with sizes ranging from 0.01 $\mu$ m - 6 $\mu$ m, wherein the ratio between the number or of particles and the number of cells ranges from 20 : 1 to 0.5 : 1, are incubated under gentle rotation for 5-10 minutes to 2 hours with cell suspensions containing the target cells at 00C to 250C, optionally followed by a per se known enrichment procedure, and evaluation of the target cell rosettes microscopically and/or by suitable visualizing or imaging devices--.

In claim 14, line 3, delete "claims 5-7" and insert --claim 5--.

## REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 3, 5, 7, 9 and 14.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicant's primary attorney-of record, Michael B. Lasky (Reg. No. 29,555), at (612) 336-4634.

Respectfully submitted,

MERCHANT, GOULD, SMITH, EDELL,  
WELTER, & SCHMIDT, P.A.  
3100 Norwest Center  
90 South Seventh Street  
Minneapolis, Minnesota 55402  
(612) 332-5300

Dated: June 18, 1999

By

  
\_\_\_\_\_  
Michael B. Lasky  
Reg. No. 29,555

MBL/sef

### Method for characterization of abnormal cells

The present invention relates to a new method for identification and characterization of eukaryotic cells.

5 In several diseases such as primary and secondary malignancies, allergic, autoimmune, inflammatory, proliferative, infectious, and destructive disorders, or diseases for which the underlying mechanisms are unclear, it would be of utmost importance to be able to determine as many as possible characteristics of cells involved in the pathologic processes. An exact  
10 determination of a number of different markers on such cells would significantly improve diagnosis, prognostication and the choice of subsequent therapy. If such a procedure is simple and rapid, it would be easy to diagnose pathological conditions at an early stage of the disease, thereby increasing the probability of selecting the best therapeutic alternative at a time when the treatment may be most effective. Moreover, in some situations  
15 it is of crucial importance to make an immediate and correct diagnosis, such as to distinguish between a benign and a malignant tumor, to guide in the surgeons' selection of a proper operative procedure.

Presently, the following diagnostic methods related to the above mentioned pathological conditions are at hand: Conventional morphological  
20 examination of tissue sections, cell cytopspins or smears, and immunological methods including immunocytochemistry, flowcytometry, and immunofluorescence microscopy. In addition, peroperative morphological evaluation of biopsied tissue specimens are performed on frozen sections.

25 With the non-immunological methods, the diagnosis can only provide distinction between normal and pathological cells based on morphological criteria.

Immunological methods such as immunocytochemistry and flowcytometry represent valuable diagnostic tools, although they suffer from several important limitations. With both methods, heterogenous cell populations are  
30 exposed to antibodies or other ligands for their binding to target cells. For flowcytometry studies live or fixed cells may be incubated to allow for fluorescence-labeled antibodies to bind to relevant membrane or intracellular antigens, before the cell suspension is analyzed in the instrument. Immunocytochemistry requires preparation of tissue sections, cytopspins or smears,

fixation and immunostaining of the cells before evaluation in a microscope. Visualization of bound antibodies is obtained indirectly through one or several steps ending with an enzyme/substrate color reaction, allowing the stained cells to be observed in a microscope. The multi-step procedure can not be completed on the day of cell sampling. Moreover, usually thorough evaluation by an experienced pathologist is needed for obtaining reliable results. For example, if the abnormal cells are being identified in a mixed cell population, and the ratio of pathological to normal cells is low, such as malignant cells in samples of bone marrow or peripheral blood, an excessive amount of work performed by a skilled pathologist may be needed for cell identification. Another problem is related to the fact that there are very few antibodies recognizing antigens that are selectively and consistently expressed in all target cells. If the objective is to identify tumor cells in blood and bone marrow, antibodies directed against "tissue-specific" markers, such as cytokeratins found in epithelial cells, are commonly used. However, as it is known that some normal cells may also express cytokeratins and that not all malignant epithelial cells do, there is a risk of both false positive and negative results.

Fluorescence-labeled antibodies can be used to detect target cells either by fluorescence microscopy or by flow cytometry. The former procedure can successfully be employed to demonstrate binding of a single antibody, although the use of morphological criteria as an additional way of distinguishing between normal and pathological cells is very limited. Moreover, the fluorescence usually fades and disappears rapidly under examination in the microscope. Thus, it is required that the fluorescence cells are studied and assessed microscopically within a short timeframe after binding of the antibody. Flowcytometric analysis requires the presence of a high number of target cells to provide reliable results. Moreover, the procedure does not provide any possibilities for morphological studies or for distinguishing between fluorescent target and non-target cells. Furthermore, several mentioned methods have the disadvantage that cells are lost in the methodological steps.

Improved possibilities for detecting target cells have recently been described (WO94/07138, WO94/07139, WO95/24648). In these procedures, antibodies bound to super-paramagnetic particles are used for detection and selection of the cells to be identified. One limitation of these methods is that it can be



difficult to prove directly the pathological nature of cells with bound particles on the surface. One advantage compared to the other described methods is, however, the simplicity of the procedure and that results can be obtained within a very short timeframe.

- 5 To further confirm the pathologic nature of stained, fluorescent or immuno-bead-binding cells it is important to characterize the target cells for more than one marker. The aim is to obtain important biological information, and information of crucial diagnostic and prognostic significance. If the number of target cells is high, flow cytometry may be used to study in parallel the  
10 binding of two different cell-bound antibodies. However, this method lacks the possibility to examine individual cells and cell morphology, and actually to identify fluorescent cells as the real target cells. Immunocytochemistry does allow for a maximum of two markers to be studied in parallel, one with conventional enzymatic visualization of bound antibody and one with a  
15 silver/gold enhancement procedure. Both multi-step procedures are relatively complicated, time-consuming and requires either expensive equipment and/or special expertise in the respective areas.

- With the immunomagnetic method, further characterization of whole cells may be obtained by preparing cytopspins of the magnetically selected cells  
20 and thereafter performing immunostaining as for conventional immunocytochemistry. Therefore, the same limitations as described for immunocytochemistry apply, and furthermore because the target cells have beads attached to their surface it may be difficult to get the cells to stick to the slides used for conventional cytopspin preparation.

- 25 US-A-5 340 719 discloses an optical screening method in which the cells are combined with one or more different sets of microspheres differing in colour or size.

- WO 94/07142 discloses an assay for the presence and relative abundance of T-lymphocyte subpopulations using different antibodies attached to a  
30 different particle. Both methods are used to isolate haematopoietic cells without specificity requirements and employ methodological steps increasing the risk for damaging the target cells.

In conclusion, the existing methods provide possibilities for studying a maximum of two independent markers, and inherent to the described methods several important problems and limitations are present. It was therefore desirable to develop a method that much more simply, rapidly, and reliably could help identifying and characterizing target pathological cells. The complexity and heterogeneity of cell biology makes it also necessary to be able to examine expression of several independent biological markers on the same cells. Such biological information would be of vital diagnostic and prognostic significance that can aid in the choice of therapeutic alternative. When several markers are examined in parallel it would be possible to obtain a more reliable confirmation of the pathological nature of the target cells, thereby improving the diagnostic reliability and help excluding false positives as well as negatives. Importantly, multi-parameter characterization could include markers of cell proliferation, cell death (such as apoptosis), adhesion, motility, invasion, antigenicity, inflammation, cell destruction, auto-immune mechanisms, angiogenesis, disease aggressiveness, tumor metastasis, and inhibitors of all these functions. Furthermore, if several markers can be examined also at an individual cell level, it would be possible to study cell heterogeneity and identifying subsets of cells with specific biological properties. In some diseases it would also be important to study pathological cells obtained from different sites in the same patient in order to determine whether cell characteristics could vary from one site to another, thus providing additional biologically and prognostically important information. Altogether, the impact of obtaining information of the type here described for clinical evaluation and treatment of patients can hardly be overestimated.

These objects are obtained in the present invention as characterized by the enclosed claims.

We here introduce a new concept in characterization of intact target cells in cell suspensions, making a direct microscopical identification of more than two membrane-associated markers possible. With this method several cell membrane markers of the origin, biology and potential fate of target cells can be studied in the same operation. The procedure is very simple and can be completed within a very short timeframe without the need for advanced and expensive instrumentation. With the method, target cells can with a minimum of handling steps, without any cell loss, be studied microscopically for the

expression of several independent marker molecules, even at the individual cell level. Thus, in addition to obtaining an overall picture of biological parameters present in the target cell population, such a procedure also allows for examining cell to cell variation in the expression of marker molecules, providing information with vital biological and medical implications.

Briefly, the method can be performed as here described: Dyed or fluorescent microspheres (beads, particles) conjugated with antibodies or ligands that can bind to cell membrane determinants to be studied are added to the cell suspension and incubated under gentle rotation. Thereafter, samples of the cell suspension are examined in a fluorescence microscope for cells with surface-bound microspheres of different light or fluorescent colors. The extent and variation in cell binding of the different microspheres can be assessed and quantitated. The assessment of cell-bound particles may, if desired, be performed by an automated procedure.

In the following the present invention is described in greater detail with the examples, which by no means are intended to restrict the invention, and figures in which:

Fig. 1 illustrates the binding of four types of microspheres to four different antigenic determinants expressed on the membrane of a target cell. The binding is in this case mediated through four different antibodies, each recognizing one of the said four antigens, in that the antibodies had first been conjugated to the respective microspheres, either directly through a chemical bond (Fig. 1, the three examples to the left), or indirectly where the beads had been pre-coated with avidin before conjugation to a biotinylated antibody (Fig. 1, right example). As illustrated in Fig.1, one antibody was bound to a blue dyed microsphere, one antibody to a small and another to a larger red fluorescent microsphere, whereas the fourth antibody had been biotin-avidin conjugated to a green fluorescent microsphere.

Fig. 2 illustrates how the invention can be used to characterize two or more cell membrane determinants in a situation where the target cells in a mixed cell suspension are rare, thus warranting an enrichment procedure before evaluation of the sample. In the illustrated case, antibody coated super-paramagnetic beads are bound to the cell membrane together with red and green fluorescent microspheres conjugated either directly or through an

avidin-biotin binding to separate antibodies. In such a situation, immuno-magnetic enrichment can be obtained by using a strong magnet that will attract cells with bound magnetic beads. The enriched cell suspension is thereafter examined in a microscope in which the binding of the fluorescent microspheres to target cells with bound magnetic beads can be observed.

The visually or instrumentally different dyed or fluorescent particles, which can be of similar or different sizes, used in the invention are conjugated to ligands such as antibodies, or fragment of antibodies, lectins and growth factors, that can bind to specific molecules expressed on membranes of abnormal cells, so that the bound particles can be identified microscopically. Examples include the use of polystyrene latex fluorescent microspheres of various colors that can be observed in a fluorescence microscope, and dyed non-fluorescent particles, such as red, yellow, green, black and blue, that can be detected by light microscopy. Antibodies conjugated to the microspheres include all those recognizing antigens, receptors, and other determinants expressed on membranes of abnormal cells, and on normal cells, see below. By combining different antibody-particle conjugates relevant for the cells to be studied, a finger-print of cell characteristics can be obtained rapidly and directly in the cell suspension. Such antigenic finger-prints would be highly valuable in evaluating important biological characteristics of cells, see above, cell populations or sub-populations. The simplicity and speed by which the method can provide such information is surprising and constitutes a key element of the invention.

Antibody-conjugated fluorescent and dyed particles have been used in various types of immunoassays to determine, e.g. the presence of free antigens, proteins, viruses and bacteria in biological fluids. With intact eukaryotic cells, fluorescent microspheres conjugated to antibodies have been used to study in each case a single molecule expressed in a specific type of normal cells, such as monocytes, lymphocytes, hepatocytes and fibroblasts. The purpose of these studies have been such as examination of the motility of membrane markers in macrophages or metabolic parameters in hepatocytes. There is no report found in the literature on attempts to study abnormal cells, such as malignant and benign neoplastic cells, and abnormal cells found in various infectious, reactive, autoimmune, inflammatory and proliferative disorders. Furthermore, combination of several antibodies conjugated to different dyed or fluorescent microspheres on the same cell

population, or on individual cells, are not described. Also, such procedures have not been employed to study, for biological or diagnostic purposes, sub-populations of target cells in a mixed population of cells.

5 The particles to be used can be fluorescent polystyrene latex microspheres or non-fluorescent particles of different colors. The size of the microspheres can be between 0.01  $\mu\text{m}$  and 6  $\mu\text{m}$ . The particles should provide possibilities for conjugating antibodies or other ligands to their surface. This may be obtained directly, such as through chemical groups like carboxyl, amino or other groups, or indirectly by binding antibodies to microspheres previously coated with proteins such as avidin, streptavidin, protein A, or with antibodies that can react with a second antibody. The size of the microspheres may be chosen to fit the size of the cells and the purpose of investigation, such that it would facilitate identification of different bound antibody-microsphere conjugates. It is considered that a particle size of e.g. 1  $\mu\text{m}$  makes identification of a relatively low number of bound particles easy, whereas a smaller size may possibly be advantageous if a marker protein expressed at high density is to be studied. Another important feature of the invention is that it can be applied both when a very low or a very high number of cells are to be examined. It is also important that the fluorescent microspheres can retain their fluorescence strength for a considerable length of time.

The antibodies recognizing the relevant membrane marker antigens or receptors could either be whole IgG of any isotype, IgM antibodies or any fragments of such antibodies, including also recombinant antibodies or antibody fragments. The novel method includes binding of the said fluorescent or dyed microspheres to target cells in a suspension with a low number of non-target cells, and in other cases where the number of target cells is low compared to non-target cells. The cell suspension is incubated with several antibodies, preferably 2-6, each conjugated to different microspheres, of the same or different sizes, of a specific dye or fluorescent color. The ratio between the number of particles and the number of target cells ranges from 20:1 to 0.5:1, preferably 5:1, limited by the size of the particles. The cell suspension should be incubated with antibody-coated beads for 5-10 minutes to 2 hours, preferably for 30 minutes, at 0°-37°C, preferably at 4°C under gentle rotation. After incubation, samples of the cell suspension is taken for evaluation in a fluorescence microscope or in other visualizing or imaging devices in which fluorescent particles and dyed

particles can be observed. Microspheres that are bound to cells can then be visualized, and the number of cells with the different types of particles attached to their surface can be assessed, with or without enumeration also of the number of beads attached to the cells. Since it is possible to use a combination of several antibody-coated microspheres, fluorescence filters suited to study different fluorescence emission spectra may be used. The method also provides possibilities for semi-automatic, video, and computer image analysis of the presence of dyed or fluorescent particles bound to the cells.

10 The antibodies could be of murine, rat, rabbit or human origin and may preferably recognize antigens present on target cells and not on normal cells in mixed cell suspensions. A list of antibodies/ligands includes, but are not limited to, those directed against groups of antigenic determinants, for example CD56/NCAM antigen, pan-epithelial EGP2/cluster2 antigen, breast  
15 mucin (MUC1) and other mucin epitopes, HMW and other melanoma-associated antigens such as gp100, MAGE 1,2 and 3, and MUC18, 80kD sarcoma associated antigen, erbB2, receptors for growth factor such as EGF, TGF, PDGF, bFCF, VEGF, IGF1, and IGF2, laminin, laminin5, uPA, uPAr, PAI, TIMP1 and 2, stromelysin, and other invasion related molecules, CEA,  
20 PSA, PSM, NSE, c-Met, CD44 and variants, ICAM-1, integrins, cadherins, catenins and other cell adhesion-associated molecules, drug resistance markers such as MDR and MRP, apoptosis-related molecules such as Fas and FasL, markers of cell proliferation, motility, differentiation, metastasis, angiogenesis, signal transduction, and inflammation-related membrane  
25 molecules, oncogene products, and chemokine receptors such as CCR 1-5, CXCR 1-4, and Duffy antigen, and all types of hematopoietic and lymphatic cell markers categorized in the CD system. Table 1 lists groups of membrane determinants that can be targeted and a number of examples within each group is also presented.

30

Table 1.

Antigens/receptors and corresponding antibodies/ligands

ANTIGENS/RECEPTORS	EXAMPLES OF ANTIBODIES/LIGANDS
<b>Adhesion molecules</b>	
Integrins	Pierce 36114, BTC 21/22, M-Kiol 2 BTC 41/42, Calbiochem 407277-84
ICAM-1 (CD54)	C57-60, CL 203.4
VCAM-1	Genzyme 2137-01
HCAM	BCA 9
LCAM	BM 1441 892
ELAM-1	Genzyme 2138-01
E-selectin	BBA 8
P-selectin	BTC 71/72
LFA-3 (CD58)	TS 2/9
MACAM-1	NKI-M9
E-cadherin	BTC 111, 6F9
P-cadherin	NCC-CAD-299
Tenascin	BM 1452 193
Thrombospondin receptor (CD36)	BM 1441 264
VLA-2	A1.43
<b>Carbohydrate antigens</b>	
T-antigen	HH8, HT-8, Lectins
Tn-antigen	TKH6, BaGs2, Lectins
Sialyl Tn	TKH-2
Galβ1-4GlcNac (nL4, 6, 8)	1B2, Lectins
Gastrointestinal cancer associated	

## Glycolipids

## Growth factor receptors

NGF receptor

## Melanoma antigens

High molecular weight antigen (HMW 250.000)	9.2.27, NrML5, 225.28
Mw105 melanoma-associated glycoprotein	ME20
100 kDa antigen (melanoma/carcinoma)	376.96
gp 113	MUC 18



p95-100	PAL-M2
gp75/TRP-1	15.75, TA99
gp 100-107	NKI-beteb
MAA	K9.2
M125kD (gp125)	Mab 436
MAGE 1, 2, 3	anti-MAGE 1, 2, 3
Tyrosinase	anti-tyrosinase

### Sarcoma antigens

TP-1 and TP-3 epitope	TP-1, TP-3
M.200kD	29-13, 29.2
M.160.kD	35-16, 30-40

### Carcinoma markers

EGP-2 (cluster 2 epithelial antigen)	MOC-31, NrLu10
MUC-1 antigens (such as DF3-epitope (gp290kD)	BM7, DF3, BCP-7 to -10
MUC-2 and MUC-3	PMH1
LUBCRU-G7 epitope (gp 230kD)	LUBCRU-G7
Prostate specific antigen	BM 1276 972
Prostate cancer antigen	E4-SF
Prostate high molecular antigen M.> 400kD	PD41
Polymorphic epithelial mucins	BM-2, BM-7, 12-H-12
Prostate specific membrane antigen (Cyt-356)	7E11-C5
Human milk fat globulin	Immunotech HMFG-1, 27.1
42kD breast carcinoma epitope	B/9189
M <sub>w</sub> > 10 <sup>6</sup> mucin	TAG-72, CC-49, CC-83
Ovarian carcinoma OC125 epitope (m. 750 kD)	OC125, OVX1
Pancreatic HMW glycoprotein	DU-PAN-2
Colon antigen Co-17-1A (M.37000)	17-1A
Ga 733.2	GA733, KS1.4

TAG 72	B72.3, CC-49, CC-83
Pancreatic cancer-associated	MUSE 11
Pancarcinoma	CC49
Prostate adenocarcinoma-antigen	PD 41
M <sub>w</sub> 150-130kD adenocarcinoma of	AF-10
M <sub>w</sub> 92kD bladder carcinoma	3G2-C6
M <sub>w</sub> 600kD bladder carcinoma	C3
Bladder carcinoma antigen	AN43, BB369
Hepatocellular carcinoma antigen	KM-2
M.900kD	
M <sub>w</sub> 48kD colorectal carcinoma	D612
Colon specific antigen	Mu-1, Mu-2
Lung carcinoma antigen M. 350-420kD	DF-L1, DF-L2
Colon cancer-associated	C242, NCRC37
Bladder carcinoma antigens	T16, T43, T138
<b>Neuroblastoma antigen</b>	
Neuroblastoma-associated, such as UJ13A epitope	UJ13A
<b>Glioma antigens</b>	
Mel-14 epitope	Mel-14
HMW 250kD	9.2.27
<b>Head and neck cancer antigens</b>	
M.18-22kD antigen	M48
<b>HLA-antigens</b>	
HLA Class 1	TP25.99
HLA-A	VF19LL67
HLA-B	H2-149.1
HLA-A2	KS1
HLA-ABC	W6.32
HLA-DR, DQ, DP	Q 5/13, B 8.11.2
β <sub>2</sub> -microglobulin	NAMB-1

**Apoptosis associated molecules**

Fas (CD95/APO-1)	Apo 1
FasL	Anti-FasL
P75	NGF

**Various**

cathepsin D	CIS-Diagnostici, Italy
neuroglandular antigen	ME91, NKI-C3, LS62
pan-human cell antigen	pan-H

**Motility related antigens**

anti-KAI-1, anti-AMF

**Proliferation-associated markers**

anti-gp120, anti-Ki-67

**Differentiation-associated markers**

MUC 18, TA99

**Drug resistant-related markers**

C 219, MRK 16, anti-MRP

**Angiogenesis-associated markers**

anti-VEGF, anti-bFGF

**Chemokine receptors markers**

anti-CCR, anti-CXCR

**Invasion-related antigens**

Antibodies to:  
PAI, MMP1, MMP9,  
TIMP1, TIMP2,  
laminin V, stromelysin,  
uPAR, uPA

The examples described below illustrates embodiments and reflect the potential of the new method for detection and characterization of target cells, not previously known by persons with knowledge in the art. It was highly surprising that mixed cell populations could be incubated simultaneously, or subsequently, with a number of different particle-bound antibodies, that for each antibody the binding of the antibody-particle complex to the target cells was specific and that the binding of different complexes could easily be visualized and distinguished in a fluorescence microscope with individual and/or several filters compatible with fluorescent emission spectra of the fluorescent microspheres, or by changing to conventional light microscopy to better identify binding of dyed non-fluorescent beads.

When several antibody-particle complexes are simultaneously incubated with target cells in a mixed cell suspension, one would easily have expected that the complexes could cluster or otherwise react with each other, forming complexes that unspecifically might bind to cells, that they for sterical or other reasons could block each others binding to target antigens, or that the fluorescence of the particles could be quenched, making it difficult to distinguish between the different types of particles. Surprisingly, however, by following the procedure according to the invention, no such problems are observed. The specificity of this approach is further demonstrated in experiments that included incubation of the target cells with one antibody-particle conjugate that would yield yellow fluorescence in the microscope, and thereafter with the same antibody coupled to a particle with a red fluorescence. In this case binding of the yellow antibody-particle conjugate was observed, whereas the binding of the second complex was completely blocked since the same antibody had been used for conjugation to both the yellow and the red particles.

In cases where the target cells in a mixed cell suspension are rare, such as tumor cells in peripheral blood and bone marrow, an enrichment procedure may be introduced before or in combination with the color/fluorescent-particle procedure. The enrichment can be obtained with different previously known approaches, including immunological procedures such as panning, column separation, or immunomagnetic positive or negative selection. If immunomagnetic selection is preferred, the same incubation step may include both the magnetizable and non-iron containing beads with the relevant cell binding antibody. After the enrichment step, the cell suspension containing the target cells can be examined and microscopically evaluated for fluorescent or dyed particle binding. Moreover, if immunomagnetic beads of a size of for example at least 1  $\mu\text{m}$  are used for enrichment, such cell-bound beads can also be observed and used as an additional cell marker (Fig. 2).

The possibility of having a rapid, simple and reliable way of simultaneously mapping expression patterns of several relevant markers on cell populations, or at an individual cell level, opens new avenues in cell biology research and for routine diagnostic, staging and prognostic evaluation of a wide range of diseases, originating in all types of human and animal tissues. In many circumstances a rapid diagnosis is of great importance in the choice of therapeutic alternative. Examples of this includes surgical procedures to be

chosen depending on whether e.g. a mammary, prostate or a brain tumor is malignant or not, whether a lymph node enlargement is caused by tumor cell infiltration or by an inflammatory reaction, on what type of cells that constitute thickening of synovial membranes in joints, what of type of cells that are present in surgical, needle, or fiberoptic biopsies from lesions in the skin, lung, liver, bone, ovaries or in the intestine and other tissues, and on what type of cells that might be present in pleural or ascitic effusions, in CSF, lymph, peripheral blood and bone marrow. At present, diagnosis of such cells are mainly based on morphological evaluations, and also on immunocytochemistry performed after preparation of tissue sections, cytopins or smears. Morphologically it can be difficult to determine the nature of the cells, and as previously mentioned immunocytochemistry can maximally detect the presence of two markers. With the new method, cells from the samples are dispersed e.g. in physiological saline or medium, incubated with relevant antibody-microsphere combinations for the necessary length of time, usually 30 minutes, and then examined microscopically. In the cell suspension, the bound particles can easily be recognized, permitting a suprisingly rapid and simple immunological fingerprinting or profile of the target cells. Because of this simplicity, the multiparameter characterization, the very short time frame needed to complete both the procedure and evaluation, the method represents a major contribution in the efforts to achieve rapid and reliable diagnosis of disease and obtain information of crucial importance for the further handling of patients.

To illustrate situations where such characterization is important the following teoretical examples are included:

In breast cancer it is known that the expression on the tumor cells of markers such as erbB2, EGF receptor, and IGF2 may be associated with increased prelifiration and agressiveness of the disease. In addition, the expression of other determinants such as EGP2, uPA<sub>r</sub>, VEGF, MUC1, MDR, Fas, and FasL can reflect characteristics that are important for the ability of the cells to metastasize, to induce angogenesis, to resist chemotherapy, as well as for apoptosis of the tumor cells or the host T-cells. By using a combination of microspheres several of these parameters can be registered simultaneously in only one operation. Such studies can be performed on the biopsies from the primary tumor, on needle biopsies from solid metastases, and on samples from ascitic or pleural effusions, blood, and bone marrow.

In HIV-infected patients, the characterization of the different subsets of T lymphocytes is of vital importance. Examples of determinants that with the new method can be studied in addition to the most common T-cell markers are chemokine receptors and apoptosis-related molecules such as Fas and FasL.

In malignant melanoma the degree or lack of differentiation of the tumor cells may reflect the potential aggressiveness of the disease in the way that lesser differentiation is related to increased malignancy. In addition, several molecules are important for immunological response, including markers such as gp100, MAGE1, 2, 3, B7, Fas and FasL. Since such markers are important for the effect of immunotherapy and vaccination, comprehensive characterization of these as well as other melanoma-associated antigens are of great importance for the clinical management of the patients. Such characterization can readily be done with the new procedure.

Lymph node enlargement can reflect different types of reactive, infectious, or malignant conditions. Thus, it may be important to determine whether such lymph nodes contain tumor cells or not. If tumor cells are present, determination of the type of malignant cells can decisively influence the choice of therapy. One example is lymph node metastasis that could originate from either a small cell lung cancer (EGP2) or a malignant melanoma (HMW250000). With the appropriate choice of antibody-microsphere conjugates this distinction can easily be made with the new approach within less than one hour.

## 25      EXAMPLES ON THE USE OF THE NEW PROCEDURE

### 1.      Specificity testing of antibody-conjugated fluorescent particles in human breast cancer cells.

MCF-7 human breast cancer cells were incubated with 1  $\mu$ m bright pink fluorescent microspheres coated with avidin, with or without biotin-conjugated MOC31 anti-EGP2 (anti-epithelial cell marker) antibody, and/or with immunomagnetic beads (4,5  $\mu$ m) coated with an anti-breast mucin (MUC1) antibody (BM7).

A suspension of MCF-7 cells incubated with fluorescent particles without bound MOC31 antibody was examined in a microscope. No fluorescent beads were attached to the tumor cells. Similar experiments with MOC31 biotin-avidin-conjugated fluorescent particles showed from 5 to 10 fluorescent particles bound to the surface of the tumor cells. In other experiments, MCF-7 cells were incubated with immunomagnetic beads coated with the BM7 antibody that bind to the tumor cells, followed by incubation with fluorescent particles with and without MOC31 antibody. It was found that the tumor cells with surface bound immunomagnetic beads showed binding also and only of MOC31-conjugated fluorescent particles. The two types of particles could easily be used in parallel, and the results showed no unspecific cell adherence of particles lacking targeting antibody.

2. Effect of simultaneous or subsequent incubation with antibody-coated beads

Human SKBr3 breast cancer cells were incubated with various combinations of bright pink fluorescent latex microspheres conjugated with MOC31 antibody, with or without simultaneous or subsequent incubation with immunomagnetic beads coated either with MOC31 or with BM7 antibodies. Bead sizes as in example 1. If both the fluorescent and immunomagnetic beads had the same targeting antibody and were incubated simultaneously, both types of beads were seen bound to the tumor cells. If either of these microspheres/beads were incubated first for 30 min and thereafter for another 30 min with the other antibody-conjugated particles, the binding of the second antibody-particle complex was completely blocked. The binding of each type of beads conjugated with different antibodies and incubated simultaneously showed the same binding pattern as that seen if each of them were studied in separate experiments.

3. Simultaneous binding of several types of microspheres/beads to the same target cells.

Breast cancer cells known to express a number of different antigens on their surface were incubated simultaneously with antibodies recognizing four different of these antigens. Each antibody had independently been conjugated to four types of microspheres/beads: 1) blue dyed latex microspheres (0.5 $\mu$ m), 2) bright pink fluorescent latex microspheres (1  $\mu$ m), 3) yellow

fluorescent microspheres (1  $\mu$ m), and 4) immunomagnetic super-paramagnetic particles (4,5  $\mu$ m). The method according to the invention showed that the tumor cells did bind all the four different types of beads which could be clearly recognized by using a combination of fluorescence and light microscopy. The number of particles attached to each cell varied for each antibody-particle complex in accordance with the known expression pattern of the corresponding antigen. The antibodies recognized the following antigens: EGP2, MUC1, EGF receptor, and an independent epithelial marker recognized by the 595 antibody.

4. Binding of fluorescent microspheres on target cells after immunomagnetic enrichment.

MCF7 human tumor cells were added to mononuclear peripheral blood cells from healthy volunteers in a ratio of 1/1000 tumor cells to mononuclear cells. The cell suspension was incubated with MOC31 anti-epithelial antibody attached to bright pink fluorescent microspheres (1  $\mu$ m) through an avidin/biotin bond and simultaneously with super-paramagnetic immunobeads (4,5  $\mu$ m) coated with the BM7 anti-MUC1 antibody. After 30 min of incubation magnetic selection of tumor cells with immunomagnetic beads bound to their surface was performed, and samples of the resulting cell suspension was examined microscopically. It was found that the remaining tumor cells with bead rosettes on their surface had also bound 5-10 fluorescent particles to the membrane, whereas a contaminating normal cells did not show binding of any of the particles/beads.

5. Binding of fluorescent cells to malignant ascitic cells

A suspension of ascitic cells drawn from a patient was brought to the laboratory without any information of the origin of the cells. The cell suspension was incubated with different antibody-coated fluorescent particles and paramagnetic immunobeads according to the invention. Particles coated with antibodies recognizing different marker antigens bound to the cells in the suspension, demonstrating the malignant and epithelial nature of the cells, thus confirming the diagnosis of ovarian cancer. In another case with ascitic fluid no cells with antibody-coated particles were seen, in agreement with the conclusion of the referring pathologist. In both cases, the method described in the invention provided the results on several different markers

00334376-064800



within 45 minutes, whereas the parallel morphological and immunocytochemical examination of a single marker was first completed more than 24 hours later.

6. Detection of cells in a pleural effusion

- 5 Without any prior knowledge of the underlying disease, incubation of the cell suspension with different anti-tumor antibodies coated onto fluorescent and immunomagnetic particles showed strong binding of all microspheres and immunobeads with anti-carcinoma and breast mucin (MUC1) antibodies. The diagnosis of the patient was breast cancer with pleural effusion.
- 10 Microspheres conjugated with an anti-melanoma antibody did not bind. In conclusion, also in this case the cells in the clinical sample were successfully identified.

7. Needle aspirate from a thyroid tumor

- 15 The cell suspension obtained from needle aspirate was incubated with fluorescent microspheres with an antibody known to react with colorectal cancer cells, and simultaneously with immunomagnetic beads coated with the MOC31 anti-epithelial antibody. The fluorescent microspheres did not bind to any types of cells in the suspension, whereas the MOC31 immunobeads bound strongly to thyroid epithelial cells but not to the high number of
- 20 macrophages present in the suspension.

- The above examples demonstrate that the new method according to the invention shows considerably increased diagnostic strength and reliability in that a higher number of target cell antigenic determinants can be deleted in one operation, in a very short period of time compared to previously known
- 25 methods.

## CLAIMS

1. Method to detect and phenotype target cells, such as animal and human cells, in cell suspensions by using particles coated with antibodies/ligands directed against antigenic determinants/receptors expressed on the target cells, except when the target cells are malignant and normal haematopoietic and lymphatic cells,  
characterized in that 2 - 6 antibodies or ligands, each antibody or ligand conjugated to each of several types of particles instrumentally or visually separable by fluorescence, color and size, with sizes ranging from 0.01 $\mu$ m - 6 $\mu$ m, wherein the ratio between the number or of particles and the number of cells ranges from 20 : 1 to 0.5 : 1, are incubated under gentle rotation for 5-10 minutes to 2 hours with cell suspensions containing the target cells at 0°C to 25°C; optionally followed by a per se known enrichment procedure, and evaluation of the target cell rosettes microscopically and/or by suitable visualizing or imaging devices.
2. Method according to claim 1,  
characterized in that the the said size of the particles ranges from 0.5 $\mu$ m - 4.5 $\mu$ m, the said ratio is 5 : 1 (number of particles/number of cells), the said incubation time is 30 minutes and the said incubation temperature is 4 ° C
3. Method according to claim 1 and 2,  
characterized in that the particles used in the method are separable by a combination of fluorescence and/or size or a combination of fluorescent emission spectra, different colors or different sizes.
4. Method according to claim 3,  
characterized in that the particles used are separable by a combination of fluorescent emission spectra and/or size.
5. Method according to claim 1-4,  
characterized in that the particles used in the method are coated with ligands/antibodies directed against adhesion molecules, carbohydrate antigens, glycolipids, growth factor receptors, melanoma antigens, sarcoma antigens, carcinoma markers, neuroblastoma antigens, glioma antigens, head and neck cancer antigens, apoptosis-associated molecules, motility-related antigens, proliferation-associated antigens, differentiation-associated

antigens, drug resistance-related antigens, angiogenesis-associated antigens, chemokine receptors, invasion-related antigens, cathepsin D, neuroglandular antigen and pan-human antigen.

6. Method according to claim 5,  
5 **characterized in** that the particles used in the method are coated with ligands/antibodies directed against the receptors/antigens listed in Table 1.

7. Method according to claims 5-6,  
**characterized in** that the particles used in the method are coated with antibodies directed to tumor associated antigens.

10 8. Method according to claim 7,  
**characterized in** that the tumor associated antigens are MOC31 anti EGP2 (anti-epithelial cell marker) antibody, anti-breast mucin (MUC1) antibody (BM7), 595, anti-EGF receptor (425.3), anti-erbB2 and anti-HMW melanoma antigen (9.2.27).

15 9. Use of the method according to claim 1-8 , wherein it is performed phenotyping of the target cells comprising profiling the antigenic determinants or receptors expressed on the cell membrane of the target cells.

10. Use according to claim 9, wherein the target cell characteristics of biologically informative markers of diagnostic, prognostic and therapeutic  
20 value are registered.

11. Use according to claim 10, wherein the target cells are malignant cells.

12. Use according to claim 10, wherein the biologically informative markers are adhesion molecules, growth factor receptors, carcinoma markers, carbohydrate antigens, melanoma antigens, sarcoma antigens, glioma  
25 antigens, apoptosis associated markers, motility related markers, proliferation associated antigens, differentiation associated markers, drug resistance markers, angiogenesis associated markers chemokine receptors, invasion-related markers and other antigens.

13. Use according to claim 12, wherein the adhesion molecules are E-cadherin, the growth factor receptors are EGFr, c-erbB2, IL-2 receptor, TNF receptor , the carcinoma markers are EGP2, MUC1, MUC2 & 3, PSA, PSM, GA733.2, TAG72, 15-3 epitope, ovarian carcinoma CA- 125 epitope, the  
30

0531376-061899

carbohydrate antigens are LeY, CEA, 15-3 epitope, the melanoma antigens are HMW 250000, gp 75/TRP-1, p95, MAG 1, 2, 3, the sarcoma antigens are TP 1 and TP 3 eptiopes, the glioma antigens such as Mel-14 epitope. apoptosis associated markers are Fas, FasL, p75, the motility related markers are KAT-1, AMF, the proliferation associated antigens are gp120, the differentiation associated markers are MUC 18, TA99, the drug resistance markers are MDR, MRP, the angiogenesis associated antigens are VEGFr, bFGF, the chemokine receptors are CCR, CXCR, the invasion-related markers are uPAR, uPA, PAI-1, TIMP1 & 2, MMP9, stromelysins, and the other antigens are cathepsin D and par-human epitope.

14. Kit to perform the method according to claim 1- 8, **characterized in** in that it comprises particles conjugated to antibodies/ ligands according to claims 5-7.

053136 061009

PCT/NO97/00342  
Intl Filing Date December 16, 1997  
Docket No. 7885.65USWO

### ABSTRACT

It is described a method to detect and phenotype target cells in cell suspensions by using particles coated with antibodies/ligands directed to antigenic determinants/receptors expressed on the target cells, characterized in that several types of particles, each particle instrumentally or visually separable by fluorescence, color and size, and each particle coated with different antibody or ligand, are incubated simultaneously or subsequently with cell suspensions containing the target cells, in connection or not with a per se known enrichment procedure, a use of the method and a kit.

09331376 051299  
662790 925560




Fig. 1

662F90" 925F660




Fig. 2

# MERCHANT & GOULD

## United States Patent Application

### COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert TITLE of invention

Method for characterization of abnormal cells

Check a or b

The specification of which

a. ☐ is attached hereto

b. ☒ was filed on

If "b" checked, complete

as application serial no.

and was amended on (if applicable)

If PCT Application

(in the case of PCT-filed application)

Insert Int. application  
number & filing date

described and claimed in international no. PCT/NO97/00342 filed 16 December 1997

and as amended on 10 February 1999 (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a). (Reprinted on back side).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent of inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

Prior applications  
Check a or b

a. ☐ no such applications have been filed.

b. ☒ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
Norway	19965531	20 December 1996	
ALL FOREIGN APPLICATIONS, IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

If "b" checked, complete

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.



U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Adriano, Sarah B	Reg. No. 34,470	Gabilan, Mary Susan	Reg. No. 38,729	Nelson, Albin J.	Reg. No. 28,650
Batzli, Brian H.	Reg. No. 32,960	Gates, George H.	Reg. No. 33,500	Pauly, Daniel M.	Reg. No. 40,123
Beard, John L.	Reg. No. 27,612	Golla, Charles E.	Reg. No. 26,896	Plunkett, Theodore	Reg. No. 37,209
Beck, Robert C.	Reg. No. 28,184	Gorman, Alan G.	Reg. No. 38,472	Pollinger, Steven J.	Reg. No. 35,326
Bejin, Thomas E.	Reg. No. 37,089	Gould, John D.	Reg. No. 18,223	Reich, John C.	Reg. No. 37,763
Berman, Charles	Reg. No. 29,249	Gresens, John J.	Reg. No. 33,112	Reiland, Earl D.	Reg. No. 25,767
Bogucki, Raymond A.	Reg. No. 17,426	Hamre, Curtis B.	Reg. No. 29,163	Schmaltz, David G.	Reg. No. 39,828
Bruess, Steven C.	Reg. No. 34,130	Hillson, Randall A.	Reg. No. 31,838	Schmidt, Cecil C.	Reg. No. 20,566
Byrne, Linda M.	Reg. No. 32,404	Hollingsworth, Mark A.	Reg. No. 38,491	Schuman, Mark D.	Reg. No. 31,197
Carlson, Alan G.	Reg. No. 25,959	Johnston, Scott W.	Reg. No. 39,721	Schumann, Michael D.	Reg. No. 30,327
Carter, Charles G.	Reg. No. 35,093	Kastelic, Joseph M.	Reg. No. 37,160	Sebald, Gregory A.	Reg. No. 33,280
Caspers, Philip P.	Reg. No. 33,227	Kettelberger, Denise	Reg. No. 33,924	Sharp, Janice A.	Reg. No. 34,051
Chiapetta, James R.	Reg. No. 39,634	Kowalchuk, Alan W.	Reg. No. 31,535	Skoog, Mark T.	Reg. No. 40,128
Clifford, John A.	Reg. No. 30,787	Kowalchuk, Katherine M.	Reg. No. 36,848	Smith, Jerome R.	Reg. No. 35,684
Conrad, Timothy R.	Reg. No. 30,164	Krull, Mark A.	Reg. No. 34,205	Stinebruner, Scott A.	Reg. No. 38,333
Cooper, Victor G.	Reg. No. 39,641	Lacy, Paul A.	Reg. No. 38,946	Sumner, John P.	Reg. No. 29,114
Crawford, Robert	Reg. No. 32,122	Lynch, David W.	Reg. No. 29,555	Summers, John S.	Reg. No. 24,216
Daignault, Ronald A.	Reg. No. 25,968	Mau, Michael L.	Reg. No. 36,204	Tellekson, David K.	Reg. No. 32,314
Daley, Dennis R.	Reg. No. 34,994	McCormack, Myra H.	Reg. No. 40,087	Underhill, Albert L.	Reg. No. 27,403
Daulton, Julie R.	Reg. No. 36,413	McDaniel, Karen D.	Reg. No. 46,602	Vandenburgh, J. Derek	Reg. No. 32,179
Davidson, Ben M.	Reg. No. 38,424	McDonald, Daniel W.	Reg. No. 37,674	Welter, Paul A.	Reg. No. 20,890
Dempster, Shawn B.	Reg. No. 34,321	McDonald, Wendy M.	Reg. No. 32,044	Williams, Douglas J.	Reg. No. 27,054
DiPietro, Mark J.	Reg. No. 28,707	Miller, William D.	Reg. No. 32,427	Wood, Gregory B.	Reg. No. 28,133
Edell, Robert T.	Reg. No. 20,187	Mueller, Douglas P.	Reg. No. 37,983	Xu, Min S.	Reg. No. 39,536
Farber, Michael B.	Reg. No. 32,612	Nasiedlak, Tyler L.	Reg. No. 40,300		
Funk, Steven R.	Reg. No. 37,830		Reg. No. 40,099		

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant & Gould to the contrary.

Please direct all correspondence in this case to Merchant, Gould, Smith, Edell, Welter & Schmidt at the address indicated below (or if no address is specified, the first address):

☒ 3100 Norwest Center, Minneapolis, MN 55402-4131      ☐ 1000 Norwest Center, St. Paul, MN 55101-2701  
Telephone No. (612) 332-5300      Telephone No. (612) 298-1055

☐ Suite 400, 11150 Santa Monica Boulevard, Los Angeles, CA 90025-3302  
Telephone No. (310) 445-1140

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Insert FULL name(s)  
AND address(es) of  
actual inventor(s)

100

200

200	2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	1	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
200	2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	2	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
3	2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	3	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
SIGNATURE OF INVENTOR 201		SIGNATURE OF INVENTOR 202		SIGNATURE OF INVENTOR 203	
DATE		DATE		DATE	

Each inventor must  
sign & date

Note: No legalization or  
other witness required

Revised 12/6/95

For Additional Inventors:

☐ Check box and attach sheet with same information, including date and signature.